Heritage is ponying up $10 million while Apotex is set to pay $39.1 million over the companies’ alleged roles in a sweeping ...

Not long after Basel, Switzerland, was selected as the next host of the annual Eurovision Song Contest, hometown pharma ...

With a positive readout for metabolic dysfunction-associated steatohepatitis (MASH) now in the bag, Novo Nordisk is gearing ...

An FDA announcement last year of an investigation into the risk of patients developing secondary cancers following the ...

In its second full quarter on the market, the fatty liver disease drug racked up sales of $62 million, which routed Wall ...

On Halloween, Lexicon was haunted again as an FDA advisory committee voted 11-3 to reject Zynquista as an accompanying ...

To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...

While Merck's oncology powerhouse Keytruda delivered another multibillion-dollar sales haul in the third quarter, regional ...

This week on "The Top Line," we explore how each presidential candidate’s approach to drug pricing could shape future policy.

A small tweak in the dosing regimen of Eli Lilly’s Alzheimer’s disease drug Kisunla has reduced brain swelling of patients in ...

It’s been about one year since Amgen closed its $27.8 billion Horizon Therapeutics buyout and brought the rare disease drug ...

Baxter International plans to exit China’s intravenous fluids market, multiple local media outlets report, citing a letter to ...